Form 8-K

8-K — UNITED THERAPEUTICS Corp

Accession: 0001104659-26-117964

Filed: 2026-10-22

Period: 2026-10-21

CIK: 0001082554

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2628087d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2628087d1_ex99-1.htm)

GRAPHIC (tm2628083d1_425img02.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2628087d1_8k.htm · Sequence: 1

false

0001082554

2026-10-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of

the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 21, 2026

United Therapeutics Corporation

(Exact Name of Registrant as Specified in its

Charter)

Delaware

000-26301

52-1984749

(State or Other

(Commission

(I.R.S. Employer

Jurisdiction of

File Number)

Identification Number)

Incorporation)

1000 Spring Street

Silver Spring, MD

20910

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code: (301) 608-9292

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant

to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.01 per share

UTHR

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging

growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of

the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with

any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On October 21, 2026, the Board of Directors of

United Therapeutics Corporation (the Company) approved a share repurchase program (the Share Repurchase Program), authorizing

the purchase by the Company of up to $2.0 billion of the Company’s common stock. This authorization will remain in effect for a

one-year period ending October 21, 2027.

On October 22, 2026, the Company issued a press

release announcing the Share Repurchase Program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form

8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description of Exhibit

99.1

Press Release dated October 22, 2026

104

Cover page Interactive Data File - the cover page XBRL tags are embedded within the inline XBRL document.

SIGNATURE

Pursuant to the requirements

of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned

hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: October 22, 2026

By:

/s/

Paul A. Mahon

Name:

Paul A. Mahon

Title:

General Counsel

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2628087d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

For Immediate Release

United Therapeutics

Corporation Announces Additional $2 Billion Share Repurchase Authorization

SILVER SPRING,

M.D. and RESEARCH TRIANGLE PARK, N.C., October 22, 2026: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation,

announced today that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the

company’s common stock, available through October 21, 2027.

“We have

the balance sheet and free cash flow to fund our long-term ambitions and the confidence to act decisively when our own shares represent

a compelling investment,” said James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics. “This

authorization is a clear reflection of our deep conviction in the future of our company, our disciplined approach to capital allocation,

and our commitment to delivering durable long-term value for shareholders.”

United Therapeutics

may implement share repurchases under the authorization through accelerated share repurchase programs, open market transactions, privately

negotiated transactions or other means. The share repurchase program does not require the purchase of any minimum number of shares, and

any share repurchases are subject to the company’s discretion and will depend on and take into account alternative uses of capital,

as well as market conditions and other factors. United Therapeutics may commence or suspend these purchases at any time without prior

notice, and assumes no obligation to utilize the authorization.

United

Therapeutics currently has an ongoing accelerated share repurchase (ASR) transaction, entered into in September 2026 under its

prior share repurchase authorization. The ASR has a scheduled termination date in the fourth quarter of 2026, subject to earlier termination

or extension in accordance with its terms, and will not reduce the amount available under the new authorization.

This press

release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer,

solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

United Therapeutics:

Enabling Inspiration

Founded by

CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics

transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative

therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical

technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients,

act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working

to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.

For Immediate Release

Forward-Looking Statements

Statements

included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the

Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding: our expectation

that we have the balance sheet to fund our long-term ambitions; our deep conviction in the future of our company, our disciplined approach

to capital allocation; our commitment to delivering durable long-term value for shareholders; the timing, structure and use of our share

repurchase program; the timing and completion of the ongoing ASR transaction; and our goals of expanding the supply of transplantable

organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices.

These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed

with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently,

such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic

reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly

Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities

Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 22, 2026, and assume no

obligation to update or revise the information contained in this press release whether as a result of new information, future events

or any other reason.

For Further Information Contact:

Investor Inquiries

https://ir.unither.com/contact-ir

Media Inquiries

communications@unither.com

GRAPHIC

Filename: tm2628083d1_425img02.jpg · Sequence: 6

Binary file (2295 bytes)

Download tm2628083d1_425img02.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 21, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 21, 2026

Entity File Number

000-26301

Entity Registrant Name

United Therapeutics Corporation

Entity Central Index Key

0001082554

Entity Tax Identification Number

52-1984749

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1000 Spring Street

Entity Address, City or Town

Silver Spring

Entity Address, State or Province

Entity Address, Postal Zip Code

20910

City Area Code

301

Local Phone Number

608-9292

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

UTHR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration